BCG-Unresponsive NMIBC: Clinical Trials & Emerging Agents
Summary of Emerging Therapies for BCG-Unresponsive NMIBC (from provided text)
This text details three emerging therapies for high-risk, BCG-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma In situ (CIS), with or without papillary tumors:
1. Nadofaragene Firadenovec-vncg (Adstiladrin)
Phase: 3
Company: Ferring Pharmaceuticals
Key Findings:
69.7% overall response rate (ORR).
51.6% complete response (CR) rate.
54.8% duration of response (DOR) at 12 months or greater.
26.6% of patients reported a treatment-related adverse event (TRAE),all grade 1/2.
Common TRAEs: dysuria (21.4%), bladder spasm (19.0%), pollakiuria (11.9%), and fatigue (11.9%).
Completion anticipated: June 2026
2. Cretostimogene Grenadenorepvec
Phase: 3
Company: CG Oncology, Inc.
Key Findings:
Overall CR rate of 75.5% (95% CI: 66.3%-83.2%).
Median duration of response of 27.9 months (95% CI, 14.3 to NE) and ongoing.
Well-tolerated, with mostly grade 1-2 AEs. No grade 3+ TRAEs reported. FDA Status: Breakthrough Therapy and Fast Track designations granted in December 2023.
Trial: BOND-003 (NCT04452591) – data presented at AUA 2025.
Completion Expected: December 2027
3. TAR-200
Phase: 3
Company: Johnson & Johnson
Key Findings:
CR rate of 82.4% (95% CI, 72.6% to 89.8%).
Median duration of response (DOR) of 25.8 months (95% CI, 8.3 to NE),with 52.9% achieving a DOR of at least 12 months.
High CR rates across subgroups (with/without papillary disease).
TRAEs reported in 83.5% of patients.
Common TRAEs: pollakiuria (43.5%), dysuria (40%), micturition urgency (24.7%), and urinary tract infection (21.2%).
FDA Status: Priority Review granted to NDA in July 2025.
Trial: SunRISe-1 (NCT04640623) – cohort 2 data presented at AUA 2025.
overall Impression: These therapies represent promising new strategies for managing BCG-unresponsive NMIBC, with high CR rates and generally manageable side effects. Further research and monitoring are ongoing.